Telix Pharmaceuticals reported a 19% increase in group revenue to US$245 million for Q3 2026, driven by strong demand for its precision medicine products Gozellix and Illuccix. The FDA approved Pixclara for glioma imaging, marking a significant milestone with first commercial doses administered in September. Telix also announced a merger with Isotope Technologies Munich SE to expand its radiopharmaceutical platform and expects FY 2026 revenue to exceed US$1 billion. The company is advancing multiple clinical trials and expanding its manufacturing capabilities to support growth and innovation in cancer diagnostics and therapeutics.
Telix Pharmaceuticals' third quarter 2026 financial performance is presented here alongside Pluang's health sector market data for context. As of Oct 21, 2026 05:01 WIB, out of 150 priced health-sector US stocks on Pluang, 129 rose and 21 fell. Among notable movers, TDOC (Teladoc Health Inc) traded at USD 6.19 with a 1-day gain of 8.03% but showed a Pluang order activity heavily skewed to selling at 99%. In contrast, SYRE (Spyre Therapeutics Inc.) priced at USD 91.40 gained 7.88% with a balanced buy/sell order activity (53% buy). RVMD (Revolution Medicines Inc.) stood at USD 196.49, up 7.87%, with a typical hold time of 5 days on Pluang.
HUTCHMED has finalized an exclusive license agreement with GSK granting GSK rights to develop and commercialize HMPL-A830, a novel KRAS-EGFR antibody conjugate therapy, outside China, Hong Kong, Macau, and Taiwan. This therapy targets cancers with KR...
Medical Informatics Corp. has launched the Sickbay Experience Demo Center at Texas Medical Center's Helix Park, showcasing its FDA-cleared Sickbay platform. This interactive center demonstrates how real-time patient data from various medical devices ...
Between Sept. 19 and Oct. 18, 2026, nearly all Ripple USD (RLUSD) payments on the XRP Ledger were tiny transfers under one unit, totaling about 7.8 million payments. These small transfers mainly came from 110 wallets sending tiny amounts to three rec...
Bitcoin's options implied volatility, measured by Deribit's DVOL index, stood at 38.28% annualized on October 20, significantly higher than the realized volatility of around 20-25% based on recent price movements. This difference reflects the forward...
Bitcoin (BTC) remained stuck below the $87,000 to $87,800 resistance range during a period of narrow trading and low volume. There is a potential supply zone near $90,000, which sits above the current resistance band. The cryptocurrency has not manag...
